The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

Part of paid clinical trials in Fairfax, Virginia.

Sponsor
Inova Health Care Services
Study ID
NCT06789757
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Memantine Hydrochloride — DRUG
    Memantine (5mg) is an N-methyl-D-aspartate (NMDA) receptor antagonist given in 21-day cycles over six months in combination with Bevacizumab and Atezolizumab. Each week memantine will be escalated by 5mg as tolerated
  • Bevacizumab — DRUG
    Bevacizumab (15mg/kg) is a vascular endothelial growth factor inhibitor given in 21-day cycles over six months in combination with Memantine and Atezolizumab.
  • Atezolizumab — DRUG
    Atezolizumab (1200mg) is a programmed death-ligand 1 (PD-L1) blocking antibody given in 21-day cycles over six months in combination with Memantine and Bevacizumab

Study Details

The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.

Key Dates

Start date
Feb 25, 2025
Status verified
Oct 2025
Primary completion
Oct 27, 2026
Completion
Jan 27, 2028

Study Design

Enrollment
19 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Addition of Memantine to Atezolizumab and Bevacizumab (the current systemic standard of care)
    The study intervention consists of the use of the triplet therapy (atezolizumab, bevacizumab, and memantine) given in 21-day cycles over six months.

Primary Outcome Measure

Objective response rate (ORR) of patients who are treated with the combination of atezolizumab, bevacizumab, and memantine. [ Time Frame: Up to 2 years ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Inova Schar Cancer Institute - Fair OaksFairfaxVirginia22033
Keary Jane't
[email protected]
571-472-3173
Arthur Winer, MD (PRINCIPAL_INVESTIGATOR)
Inova Health Care ServiceFalls ChurchVirginia22042
Elahe Mollapour
[email protected]
571-472-0615
Keary Jane't
[email protected]
571-472-3173
Arthur Winer (PRINCIPAL_INVESTIGATOR)

Find similar trials in Fairfax, VA

By condition
Liver cancer
By specialty
OncologyGI oncologyHepatology
By research site
Inova Schar Cancer Institute - Fair Oaks· Fairfax, VAInova Health Care Service· Falls Church, VA

Related Studies